(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr. Andrew Berchuck, researchers have made important breakthroughs toward understanding the risk and growth of a certain kind of ovarian cancer, known as mucinous ovarian carcinoma, or MOC. The international study involving 1,644 women with MOC and … Continued
(June 18, 2015) A team of researchers, including OCRF grantees Juan Cubillos-Ruiz, PhD, and Alfredo Perales-Puchalt, MD, have discovered how ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor. The findings are published in the June 11 issue of Cell. A therapy that … Continued
(June 17, 2015) Researchers at MD Anderson Cancer Center in Houston have identified a new class of gene mutations that may contribute to outcomes in the treatment of ovarian cancer. Research on the gene family known as ADAMTS could open up a new genetic avenue for the design of ovarian cancer therapies. The findings were … Continued
(June 5, 2015) The Society of Gynecologic Oncology has posted three short videos on YouTube that highlight some of the ovarian cancer research findings presented at the American Society of Clinical Oncology annual meeting last week. Click here to watch the videos, which highlight the results of a number of ovarian cancer clinical trials.
(May 28, 2015) In an effort to study treatment options for high-grade serous ovarian cancer, scientists from the University of Queensland and Sydney’s Millennium Institute collected DNA from 92 patients to find out what makes those cells so resistant to chemotherapy. OCRF Scientific Advisory Committee members Ronny Drapkin, MD, PhD, and Ernst Lengyel, MD, PhD, … Continued
(May 28, 2015) A recent study performed in the UK and New Zealand revealed that having chemotherapy treatments before and after surgery is associated with a higher quality of life when compared to those who undergo surgery before chemotherapy. The study, which included 550 women with Stage III or IV ovarian cancer, concluded that shrinking … Continued
Introducing the 2015 Ovarian Cancer National Conference Rosalind Franklin Excellence in Ovarian Cancer Research Award winner: Beth Karlan, MD. The Rosalind Franklin Excellence in Ovarian Cancer Research Award is named for the molecular biologist Dr. Rosalind Elsie Franklin, who played a vital role in discovering the structure of DNA. Her career was cut short in 1958 when she died of ovarian cancer at age 37. Throughout her life, she was a committed researcher; this award honors an individual who continues her legacy of excellence. Beth Karlan, MD is the Director of the Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, and Director of the Gilda Radner Hereditary Cancer Program. Click the plus sign to read more.
Research Advocate Seana Roubinek attended the 2015 American Association of Cancer Research Annual Meeting in April. Here is her report: “As a two-time cancer ovarian cancer survivor, I have had the great opportunity to get involved in legislative advocacy as well as the Survivors Teaching Students® program through the Ovarian Cancer National Alliance. Being selected … Continued
(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from the study will be published in the Journal of Clinical Oncology. Using an algorithm to analyze changes in the level of CA-125 (a protein in … Continued
(April 29, 2015) A study published in JAMA Oncology last Saturday concluded that an oophorectomy, the surgery to remove ones ovaries, has a substantial impact on survival rates for those diagnosed with stage I or II breast cancer who also tested positive for the BRCA1 mutation. Involved in the study were 676 women, 345 of whom had … Continued
On April 23, the drug manufacturer Mylan N.V. announced a voluntary nationwide recall of select lots of several drugs used in the treatment of ovarian cancer. The nationwide recall includes several formulations of injectable gemcitabine and cytarabine. While no adverse events have been reported with the use of these drugs, patients who may be experiencing problems related to these drugs should contact their physicians. Expand the post for more information about the recall.
Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition Team-Up to Fund Game-Changing Ovarian Cancer Research Today the members of the new Stand Up To Cancer-Ovarian Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational Research Dream Team were announced. The Dream Team will focus on “DNA Repair Therapies for … Continued
Get email updates about research news, action alerts, and ways to join the fight.
